Navigation Links
United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
Date:10/20/2011

SILVER SPRING, Md., Oct. 20, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its third quarter 2011 financial results before market open on Thursday, October 27, 2011.

United Therapeutics will host a half-hour teleconference on Thursday, October 27, 2011, at 9:00 a.m. Eastern Time.  The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-855-859-2056, with international callers dialing 1-404-537-3406, and using conference code: 16451381.

This teleconference is also being webcast and can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm.  [uthr-g]

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
2. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
3. Full-day "United Nations" Online Investor Conference: October 6th at RetailInvestorConferences.com
4. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
5. FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States
6. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
7. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
8. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
9. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
10. United Therapeutics Corporation to Announce Fourth Quarter and Annual 2010 Financial Results Before Market Open on Tuesday, February 15, 2011
11. United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 E-QURE Corp. (OTCQB: ... its Bio-electrical Signal Therapy device ("BST Device"), a new ... to heal chronic wounds, today announced that the Company ... Israeli distributor specializing in medical devices, for the marketing ... is a 70 years old, sales, marketing and distribution ...
(Date:7/31/2015)... , July 31, 2015 In ... resources that help them drive positive health outcomes, ... vital source of patient care in their communities. ... annual tradeshow and conference, AmerisourceBergen announced a new ... Pharmacy Services Administration Organization and help independent pharmacies ...
(Date:7/30/2015)... 30, 2015 AACC welcomed thousands of ... AACC Annual Meeting & Clinical Lab Expo in ... The meeting showcased revolutionary advancements in clinical testing ... healthcare providers to diagnose patients quickly and accurately ... As of Wednesday, July 29, ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... of a field clinical study of its canine osteoarthritis stem cell product, currently ... Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. ...
Breaking Biology Technology:E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3
... Transposagen Biopharmaceuticals, Inc . ... genetic modification technology, have announced a non-exclusive marketing and distribution ... ™ technology. The piggyBac ... Modification System enables researchers to: Alter the ...
... CARLSBAD, Calif., May 11, 2011 Life Technologies Corporation ... that over 3,800 of its employees worldwide are scheduled to ... benefit their communities as part of the company,s eighth annual ... than 15,000 hours of community service at 48 sites in ...
... Technologies, Inc. today announced that positive preclinical data ... Paris, France on May 18, 2011 in a ... DES with a Fully-absorbable Coating and Enhanced Drug ... ("MiStent DES") is an ultra-thin, advanced alloy drug-eluting ...
Cached Biology Technology:Transposagen's piggyBac™ Vectors to be Distributed by System Biosciences 2Transposagen's piggyBac™ Vectors to be Distributed by System Biosciences 3Life Technologies Employees 'Give Back' to Their Communities During Eighth Annual Global Volunteer Day 2Life Technologies Employees 'Give Back' to Their Communities During Eighth Annual Global Volunteer Day 3Life Technologies Employees 'Give Back' to Their Communities During Eighth Annual Global Volunteer Day 4Life Technologies Employees 'Give Back' to Their Communities During Eighth Annual Global Volunteer Day 5Micell Technologies Reports Preclinical Data for MiStent™ Drug-Eluting Coronary Stent to be Presented at EuroPCR 2Micell Technologies Reports Preclinical Data for MiStent™ Drug-Eluting Coronary Stent to be Presented at EuroPCR 3
(Date:7/31/2015)... , 31 de julho de 2015 A ... www.icg-10.org ) será realizada pela BGI de 22-25 de outubro ... A conferência está celebrando seu 10 o. ... a ICG se tornou uma das reuniões mais influentes ... encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
(Date:7/27/2015)...   Zynx Health ™, the market leader ... today announced that its ZynxCarebook ™ mobile ... smartphones and tablets. With this expansion, care team ... ZynxCarebook to securely exchange messages and share assessments ... to other care settings, and improve clinical outcomes ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... nine out of 10 new cancer drugs successfully ... in human clinical testing. A new partnership facilitated ... outcome. The partnership brings together The UC ... National Cancer Institute,s (NCI) Center for Advanced Preclinical ...
... image shows the huge plume of sulphur dioxide that spewed ... Andes about 600 km south of Santiago. After lying ... earthquakes signalled the beginnings of this major volcanic eruption. On ... volcanic ash and gas over 10 km high. ,Several thousand ...
... Bethesda, MD The Federation of American Societies ... its newest client, the International Conference on Human Immunity ... Emory Conference Center in Atlanta, Georgia, on April 13-14, ... provide meeting management services. One of the organizers, ...
Cached Biology News:NCI partners with Jackson Laboratory, UC Davis to speed cancer clinical trials 2NCI partners with Jackson Laboratory, UC Davis to speed cancer clinical trials 3
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Chicken polyclonal to HADHSC - Azide free ( Abpromise for all tested applications). Antigen: Amino acids 57-314 of HADHSC Entrez GeneID: 3033 Swiss Protein ID: Q16836...
Biology Products: